Treatment duration for patients with drug-resistant tuberculosis, United States.
Carla A
CA
Winston
Kiren
K
Mitruka
D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D012293:Rifampin / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D014481:United States / Q000453:epidemiology
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin